@article {1593864,
	title = {Decreased risk of non-infectious anterior uveitis with statin therapy in a large healthcare claims database},
	journal = {Graefes Arch Clin Exp Ophthalmol},
	volume = {259},
	number = {9},
	year = {2021},
	month = {2021 Sep},
	pages = {2783-2793},
	abstract = {PURPOSE: The purpose of this study is to determine if statin therapy decreases the incidence of non-infectious uveitis (NIU) using a retrospective cohort study. METHODS: Patients enrolled in a national insurance plan who initiated statin (n = 711,734, statin cohort) or other lipid-lowering therapy (n = 148,044, non-statin cohort) were observed for NIU development. Incident NIU in the primary analysis was defined as a new diagnosis code for NIU followed by a second instance of a NIU code within 120\&nbsp;days. For the secondary outcome definition, a corticosteroid prescription or code for an ocular corticosteroid injection within 120\&nbsp;days of the NIU diagnosis code was used instead of the second NIU diagnosis code. Estimation of NIU incidence used multivariable Cox proportional hazards regression. The proportional hazards assumption was satisfied by creating two time periods of analysis, <= 150 and \&gt; 150\&nbsp;days. Subanalyses were performed by anatomic subtype. RESULTS: Overall, the primary outcome occurred 541 times over 690,465 person-years in the statin cohort and 103 times over 104,301 person-years in the non-statin cohort. No associations were seen in the <= 150-day analyses (p \&gt; 0.20 for all comparisons). However, after 150\&nbsp;days, the statin cohort was less likely to develop any uveitis [hazard ratio (HR) = 0.70, 95\% confidence interval (CI): 0.51-0.97, P = 0.03] in the primary outcome analysis, but did not meet significance for the secondary outcome (HR = 0.85, 95\% CI: 0.63-1.15, P = 0.30). Similarly, in the anatomic subtype analysis, after 150\&nbsp;days, the statin cohort was less likely to develop anterior uveitis (HR = 0.67, 95\% CI: 0.47-0.97, P = 0.03) in the primary analysis, but the association did not reach significance for the secondary outcome (HR = 0.82, 95\% CI: 0.56-1.20, P = 0.31). CONCLUSION: Our results suggest that statin therapy for \&gt; 150\&nbsp;days decreases the incidence of NIU.},
	keywords = {Delivery of Health Care, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Retrospective Studies, Uveitis, Uveitis, Anterior},
	issn = {1435-702X},
	doi = {10.1007/s00417-021-05243-8},
	author = {Sobrin, Lucia and Yu, Yinxi and Han, Samuel and Susarla, Gayatri and Kempen, John H and Hubbard, Rebecca A and VanderBeek, Brian L}
}
